CTX Technology acquires new drug delivery tech; FDA to review topical-barrier cream;

> CTX Technology has acquired the IP, formulations and related data of Convoy Therapeutics. The drug delivery tech can apparently transport small and large molecules, including biologics, into the skin, and enable localized placement. It has both therapeutic and aesthetic applications. More

> The FDA agreed to review Cipher Pharmaceuticals' submission for Dermadexin topical-barrier cream under its 510(k) pathway for low- to moderate-risk medical devices. The candidate is intended to treat the skin disorder seborrheic dermatitis. More

Suggested Articles

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.